By Suherman Candra Maholtra 
A groundbreaking study from the University of Virginia School of Medicine has revealed that severe cases of COVID-19 and influenza can cause lasting damage to the lungs, creating a "pro-tumor" environment that facilitates the development and rapid progression of lung cancer. The research, published in the prestigious scientific journal Cell, indicates that the immunological "scarring" left behind by severe respiratory distress can persist for months or even years, fundamentally altering the cellular landscape of the lungs. However, the study also offers a significant silver lining: vaccination against these viruses appears to effectively mitigate these long-term risks by preventing the initial severity of the infection.
Led by Jie Sun, PhD, a scientist at the UVA School of Medicine and co-director of the Beirne B. Carter Center for Immunology Research, the research team discovered that the risk is specifically tied to the severity of the initial illness. While mild cases of respiratory infection do not appear to increase cancer risk—and may even correlate with a slight decrease—severe infections that require hospitalization or cause significant lung injury leave a lasting inflammatory footprint. This discovery has immediate implications for how the medical community monitors survivors of severe viral pneumonia, suggesting that these individuals may require long-term surveillance similar to that currently provided for chronic smokers.
The Biological Mechanism: How Infections Fuel Malignancy
The core of the UVA study lies in the discovery of how severe viral infections reprogram the immune system within the lung tissue. Under normal circumstances, immune cells like neutrophils and macrophages act as the body’s first line of defense, identifying and destroying pathogens or early-stage cancerous cells. However, following a severe bout of COVID-19 or influenza, these cells can undergo a maladaptive transformation.
The researchers observed that in the wake of a severe infection, certain neutrophils—a type of white blood cell—begin to behave abnormally. Instead of maintaining their defensive posture, they contribute to a persistent, chronic inflammatory state. This environment becomes "pro-tumor," essentially acting as a fertile soil for cancer cells to take root and multiply. Furthermore, the study identified significant changes in the epithelial cells that line the lungs and the alveoli, the tiny air sacs responsible for gas exchange. These structural cells become more susceptible to oncogenic (cancer-causing) transformations when exposed to the chronic inflammatory signals sent by the reprogrammed immune system.
This "immune scarring" serves as a bridge between the acute infection and the eventual development of malignancy. By analyzing mouse models and human patient data, the team demonstrated that the lungs do not simply return to a "baseline" state after the virus is cleared. Instead, the severe injury triggers a long-term shift in the local microenvironment that suppresses the body’s natural anti-tumor immunity while promoting the growth of latent cancer cells.
Statistical Evidence: A 1.24-Fold Increase in Risk
To validate their laboratory findings, the UVA researchers conducted an extensive analysis of patient data, focusing on individuals who had been hospitalized for COVID-19. The results provided a clear statistical link between severe respiratory illness and subsequent cancer diagnoses. The analysis revealed a 1.24-fold increase in lung cancer incidence among those who survived severe COVID-19 compared to those who did not experience severe infection.
Critically, this elevated risk remained consistent even after the researchers accounted for common confounding factors, such as smoking history, age, and existing comorbidities. This suggests that severe viral injury is an independent risk factor for lung cancer. The data also highlighted a stark contrast between severe and mild cases. Individuals who experienced only mild respiratory symptoms did not show an increased risk of cancer. In fact, some data points suggested a marginal decrease in incidence among mild cases, potentially due to a temporary "priming" of the immune system, though this remains a subject for further investigation.
"The findings carry significant implications for clinical care," the researchers noted in their report. With tens of millions of people worldwide having experienced severe COVID-19 or other forms of viral pneumonia over the last several years, the potential public health impact of this increased cancer risk is substantial.
Vaccination as a Critical Preventative Tool
One of the most vital takeaways from the study is the protective role of vaccination. The researchers found that prior vaccination largely blocked the harmful lung changes that lead to cancer growth. Vaccines function by preparing the immune system to recognize and neutralize the virus quickly, which prevents the infection from reaching the level of severity required to cause long-lasting lung damage.
By ensuring that an infection remains mild, vaccines effectively prevent the "pro-tumor" environment from ever forming. Dr. Sun emphasized that the benefits of vaccination extend far beyond the immediate prevention of hospitalization or death. "We also believe that vaccines don’t just prevent acute hospitalization after contracting the virus," Sun said. "They may also reduce the long-term fallout of severe infection, including the kind of immune scarring that can increase cancer risk."
This adds a new dimension to the public health argument for routine vaccination against influenza and COVID-19. Beyond preventing acute respiratory distress, these vaccines may serve as an indirect form of cancer prevention by maintaining the integrity of the lung’s immune landscape.
A New Paradigm for Lung Cancer Surveillance
The study’s findings are prompting a re-evaluation of how patients are monitored following recovery from severe respiratory illness. Jeffrey Sturek, MD, PhD, a UVA physician-scientist and collaborator on the study, noted that the medical community has long recognized smoking as the primary risk factor for lung cancer. However, these new results suggest that a history of severe viral pneumonia should perhaps be treated with similar gravity.
"The results from this study suggest that we may need to think about severe respiratory viral infection similarly [to smoking]," Sturek explained. Currently, high-risk individuals—primarily long-term smokers—are encouraged to undergo routine screening with low-dose CT scans to detect lung cancer in its earliest, most treatable stages. The UVA team suggests that a similar protocol might be beneficial for patients who have survived severe lung injury from COVID-19 or the flu.
Early detection is the single most important factor in lung cancer survival. By identifying a new high-risk population, healthcare providers can potentially catch malignancies years earlier than they otherwise would have. The researchers recommend that doctors closely monitor the long-term pulmonary health of survivors of severe viral pneumonia, especially those who have other risk factors like a history of smoking.
Institutional Context and Future Research
This research was conducted as part of the broader mission of the UVA Paul and Diane Manning Institute of Biotechnology and the UVA Comprehensive Cancer Center. The Manning Institute is dedicated to accelerating the transition of laboratory discoveries into clinical treatments, while the UVA Comprehensive Cancer Center is one of only 57 centers in the nation to hold the "comprehensive" designation from the National Cancer Institute.
The study was supported by a wide array of grants from the National Institutes of Health (NIH) and various philanthropic organizations, reflecting the high priority placed on understanding the long-term sequelae of the COVID-19 pandemic. The multidisciplinary team included experts in immunology, infectious diseases, and oncology, highlighting the complex nature of the interaction between viral pathogens and cancer biology.
Moving forward, the UVA team plans to investigate whether the "pro-tumor" environment created by viral infections can be reversed. Future studies may explore pharmacological interventions designed to "reset" the immune cells in the lungs after a severe infection, potentially stripping away the pro-cancer conditions before a tumor can develop.
Implications for Public Health and Policy
The discovery that severe infections can act as a catalyst for cancer development marks a significant shift in our understanding of post-viral health. It highlights the fact that the "recovery" phase from a pandemic or a severe flu season lasts much longer than the period of active infection. As health systems continue to manage the long-term effects of the COVID-19 pandemic—often referred to as "Long COVID"—this study provides a specific biological mechanism for one of the most serious potential outcomes.
From a policy perspective, these findings underscore the importance of maintaining robust vaccination programs and ensuring that patients who suffer severe respiratory events have access to long-term follow-up care. The economic and human cost of a delayed lung cancer diagnosis is immense; by integrating viral history into cancer risk assessments, the medical community can move toward a more proactive and personalized model of preventative medicine.
In summary, while severe respiratory infections like COVID-19 and influenza pose an immediate threat to life, their ability to reshape the lung’s immune environment creates a lingering danger that can manifest as cancer years down the line. Through the dual approach of widespread vaccination and enhanced clinical surveillance for those who have suffered severe illness, the medical community can work to mitigate this newly identified risk and improve long-term outcomes for millions of survivors worldwide.
